New Analysis Offers Insight Into Who May Benefit Most From jCell Therapy

CIRM has followed jCyte‘s progress for years, and for good reason.

The company’s stem cell therapy for retinitis pigmentosa (RP) continues to generate encouraging results. Researchers have now taken a closer look at the clinical trial data and identified a potential marker that may predict which patients are most likely to benefit from treatment.

That finding could help guide future studies and improve outcomes for patients with this devastating disease.

A Potential New Treatment for Retinitis Pigmentosa

Retinitis pigmentosa is a rare inherited disorder that gradually destroys the retina’s light-sensing cells.

The disease affects rods and cones, the cells that detect light and transmit visual information to the brain.

Patients often first notice difficulty seeing in low light. Over time, they lose more of their vision until many become legally blind.

RP typically appears early in life. Many patients receive a diagnosis during their teenage years and experience significant vision loss by middle age.

There are currently no approved treatments that can stop or reverse the disease.

Researchers estimate that RP affects approximately 100,000 people in the United States and up to two million people worldwide.

Expanding Islands of Vision

To address this unmet need, jCyte developed jCell, a therapy made from human retinal progenitor cells derived from adult stem cells.

Doctors inject these cells into the back of the eye.

Once in place, the cells release neurotrophic factors, proteins that help support and protect existing retinal cells.

The goal is not to replace damaged photoreceptors. Instead, the therapy aims to preserve the cells that remain and improve their function.

According to jCyte co-founder Dr. Henry Klassen, RP does not simply cause vision to narrow evenly over time.

Instead, patients often retain isolated pockets of vision surrounded by areas of vision loss.

Researchers measured these remaining “islands of vision” throughout the trial.

Following treatment, many of those islands expanded.

That expansion suggests the therapy may help preserve and strengthen surviving photoreceptors.

Encouraging Results From the Clinical Trial

Researchers followed patients for one year after treatment.

Patients who received the highest dose, six million cells, showed the greatest improvement.

On average, these participants could read 16 more letters on a standard eye chart compared with their baseline performance.

By comparison, patients who received a sham treatment improved by fewer than two letters.

Researchers also observed improvements in several other measures of visual function.

Treated patients demonstrated:

  • Better peripheral vision.
  • Improved contrast sensitivity.
  • Greater ability to distinguish objects from their background.
  • Enhanced navigation in low-light environments.

Together, these findings suggest the therapy may improve both measured vision and everyday visual function.

Identifying Patients Most Likely to Benefit

The team also performed a deeper analysis of the clinical trial data.

Dr. Sunil Srivastava of the Cleveland Clinic Cole Eye Institute examined characteristics associated with better outcomes after treatment.

His analysis identified central foveal thickness (CFT) as a potential predictor of response.

The fovea sits at the center of the retina and plays a critical role in sharp, detailed vision.

Patients who entered the study with greater central foveal thickness tended to experience the largest benefits from jCell.

This insight could help researchers refine future trials and identify patients most likely to respond to treatment.

Looking Ahead

The findings arrive at an important time for the program.

jCyte plans to apply these lessons to its upcoming pivotal clinical study.

“We look forward to working closely with our scientific advisory board and principal investigators to apply these key learnings to our upcoming pivotal study of jCell,” said jCyte CEO Dr. Shannon Blalock.

For people living with retinitis pigmentosa, the need remains urgent.

Patients currently have few treatment options and no cure.

While additional studies are necessary, the latest results suggest that stem cell-based therapies may help preserve vision and improve quality of life for people facing progressive blindness.

The new analysis also demonstrates how researchers can use clinical data to better understand who benefits most, bringing the field one step closer to a personalized approach to treating retinal disease.

2 thoughts on “New Analysis Offers Insight Into Who May Benefit Most From jCell Therapy”

  1. My sister has retinitis pigmentosa. She is 63 and was diagnosed at 25. Hers is very bad with peripheral loss,, no night vision, tunnel vision, and is losing color differentiation. Is it too late for her to be included in a clinical trial?

    • Dear Kaye, I’m so sorry to hear about your sister. I can only imagine how challenging that must be for her. The company behind the clinical trial we funded is jCyte. If you go to their website, http://www.jcyte.com, you will find a lot of information about the procedure, how it works and how you can contact them to find out more about possible future clinical trials. I hope that helps. Yours , Kevin

Leave a Reply